banner

ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer

ALR Technologies, Inc. (ALRT)

Health information company ALR Technologies, Inc. (OTCBB: ALRT) on Monday disclosed the appointment of William S. Smith as Chief Commercial Officer and member of the Board of Directors, effective January 1, 2013.  Smith will oversee sales and marketing, investor relations, public affairs, communications and government affairs, according to a corporate statement.

Bill Smith

Previously, Smith spent ten years as Vice President of U.S. Public Affairs and Policy at Pfizer, Inc. (NYSE: PFE), where he was the lead advisor on U.S. policy issues to Pfizer’s U.S. commercial businesses.

Most recently, he was Managing Director of Healthcare at NSI, LLC, a Washington, D.C.-based consulting firm, where Smith advised pharmaceutical, biotechnology and medical device companies, including AstraZeneca PLC (NYSE: AZN), Merck & Co. (NYSE: MRK), Genzyme Corp. (acquired by Sanofit-Aventis (NYSE: SNY) in 2011 for $20.1 billion), MedImmune, Inc. (acquired by AstraZeneca in 2007 for $15.6 billion), and Brussels, Belgium-based global biopharmaceutical company UCB S.A.

Smith also worked in government as a staff member of two Massachusetts Governors, a leadership aide to the Rupublican Leadership in the U.S. House of Representatives and a senior aide in the White House Office of national Drug Control Policy under President George H.W. Bush.

“I am delighted to welcome Mr. Smith to ALR Technologies,” said ALRT chief executive Sidney Chan. “He has deep experience in the healthcare marketplace and he has significant experience building and leading a large organization. As a consultant, he provided ALRT with invaluable strategic counsel on our key markets and business model. As we now enter the commercial phase of our key product, he will build a world class organization to support our growth.”



“I am very excited to join ALR Technologies,” said Mr. Smith. “The company has developed a technology and a business model that is precisely in the space where healthcare is going. The company has huge potential for growth and its future success would represent a great opportunity for patients with diabetes to better control their condition.”

Smith is referencing ALR’s Health-e-Connect system, a web-based patient management platform for medical professionals to improve compliance and adherence to care plans of patients in their homes.  The company has indicated that the system is expandable to manage a wide array of diseases, but is keeping their initial commercialization initiatives focused on diabetes, a chronic disease impacted tens of millions of patients in the United States that has seen exponential diagnosis rates in recent years.

Shares of ALRT closed trading Monday at 3.3 cents.

ALR Technologies (ALRT) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation, journalism and video presentation production services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page.
Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Cellceutix Targeting Gram-Negative and Candida Fungal Infections

Cellceutix Targeting Gram-Negative and Candida Fungal Infections(0)

Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally – and taking the headline – the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

read more
banner

Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.